skip to main content
Global Search Configuration
Sponsored and supported by:

The Global Generics & Biosimilars Awards 2023 are open for entries

Join us for the 10th anniversary of the Global Generics and Biosimilars Awards celebrating the greatest achievements and innovations across the development, authorisation, marketing and distribution of global off-patent pharmaceuticals.

Co-locating with CPhI Worldwide in Barcelona, these illustrious awards provide a unique opportunity for the industry to come together to discuss future opportunities and challenges and shine a light on the companies and individuals driving positive change. Winners will be recognised across 14 categories, including Biosimilar Initiative of the Year, Leader of the Year, API Supplier of the Year and new for 2023, Campaign of the Year.

KEY DETAILS
  • Entries close Monday, 4 September, 2023
  • Ceremony: Wednesday, 25 October, 2023
  • Free to enter
  • Hotel Porta Fira, Barcelona

The Global Generics and Biosimilars Awards are free to enter. The closing date for entries is Monday, 4 September, 2023, and the qualifying period for submissions is 1 August 2022 - 31 August 2023. The judging process will take place over the summer. The finalists will be announced in September and the winners revealed at the Awards on 25 October 2023.

THE GLOBAL GENERICS & BIOSIMILARS AWARDS CATEGORIES 2023

Download the entry guide

Open to any company that generates at least a third, or at least US $250 million, of its annual sales from generics or biosimilars.

WHAT YOU NEED TO KNOW:

Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. The activities in question should have taken place between 1 August 2022 – 31 August 2023.

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Open to any company that generates at least a third, or at least US$250 million, of its annual sales from generics and biosimilars. Qualification for a region is dependent on the headquarters (not tax domicile) of a company’s generics and/or biosimilars business.

  • Company of the Year – Americas
  • Company of the Year – Asia-Pacific
  • Company of the Year – EMEA

WHAT YOU NEED TO KNOW

Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. The activities in question should have taken place between 1 August 2022 – 31 August 2023.

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Open to any company which has acquired another company that is active in generics and/or biosimilars, or has acquired a portfolio of generic and/or biosimilar products.

WHAT YOU NEED TO KNOW

Evidence cited in supporting text could include: details of the expected benefits of the acquisition, including anticipated synergies and integration goals as well as strategic or cultural fit. The activities in question should have taken place between 1 August 2022 – 31 August 2023.

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Open to any member of the senior management team of a firm within the generics or biosimilars industries. Judges will want to see how the entered leaders have best applied company values within the business environment – achieving measured and sustainable growth, driving improved performance, delivering shareholder value, implementing robust strategies, engaging staff, demonstrating market knowledge and true customer insight.

WHAT YOU NEED TO KNOW

Evidence cited in supporting text could include: evidence of successful strategies or initiatives implemented, executive team management, industry-level leadership or positive effects on company culture. The activities in question should have taken place between 1 August 2022 – 31 August 2023.

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Entries in this category could include known molecules that are repurposed for new indications, reformulated in a way that adds value for patients, put together in innovative combinations, or which feature added-value packaging or delivery methods.

WHAT YOU NEED TO KNOW

Evidence cited in supporting text could include: innovation, addressing unmet needs, overcoming regulatory or technology obstacles, intellectual property triumphs or marketing success. The activities in question should have taken place between 1 August 2022 – 31 August 2023.

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Open to any generics and/or biosimilars alliance, joint venture, distribution agreement, licensing deal or similar that does not involve the acquisition of another company or a portfolio of products.

WHAT YOU NEED TO KNOW

Evidence cited in supporting text could include: details of the expected benefits of the business development activities, including anticipated financial or strategic advantages. The activities in question should have taken place between 1 August 2022 – 31 August 2023.

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Open to any company supplying off-patent active pharmaceutical ingredients (APIs) or intermediates.

WHAT YOU NEED TO KNOW

Evidence cited in supporting text could include: details of manufacturing excellence, supply security, customer service, technological achievements or increased efficiencies. The activities in question should have taken place between 1 August 2022 – 31 August 2023.

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Entries may relate to any biosimilar currently marketed, approved or in clinical development, sales and marketing initiatives, distribution agreements or other initiatives aimed at increasing biosimilar usage.

WHAT YOU NEED TO KNOW

Evidence cited in supporting text could include: strategic advantages, details of overcoming development or technology obstacles, manufacturing efficiency or intellectual property triumphs. The activities in question should have taken place between 1 August 2022 – 31 August 2023.

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

This category allows industry firms and organizations to highlight outstanding campaigns used to successfully promote and highlight generics, biosimilars and value-added medicines across the world. This could include awareness campaigns, efforts to highlight key industry contributions to a wider audience, or initiatives that raise the profile of off-patent medicines for healthcare industry stakeholders.

WHAT YOU NEED TO KNOW

Evidence cited in supporting text could include: industry thought leadership, outreach achieved, social media and media interest or collaboration with regulatory authorities. The activities in question should have taken place between 1 August 2022 – 31 August 2023.

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Awarded to identify excellence in the regulatory sphere. This could include innovative approaches to obtaining marketing authorisations, regulatory milestones for individual companies, or developments that represent a wider breakthrough for the global generics and/or biosimilars industries.

WHAT YOU NEED TO KNOW

Evidence cited in supporting text could include: details of overcoming development or technology obstacles, competitive advantages, regulatory efficiency or benefits to patient populations. The activities in question should have taken place between 1 August 2022 – 31 August 2023.

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Humanitarian charity International Health Partners (IHP) has partnered with Generics Bulletin to create this Award. Entries could include: company approach to CSR, implementation, engagement plans, raining & education programmes, compulsory licensing and humanitarian aid donations.

WHAT YOU NEED TO KNOW

Evidence cited in supporting text could include: details of the positive impact of CSR activities, innovative or original approaches to CSR, or positive corporate cultural changes. The activities in question should have taken place between 1 August 2022 – 31 August 2023.

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Awarded to recognize outstanding achievements by firms or individuals that work alongside generics and biosimilars manufacturers and suppliers. These could include logistics providers, contract-research organisations, contract-manufacturers, law firms and consultants.

WHAT YOU NEED TO KNOW

Evidence cited in supporting text could include: details of outstanding collaborations with generics, biosimilars or value-added medicines suppliers, customer service, or innovations benefiting the off-patent industry. The activities in question should have taken place between 1 August 2022 – 31 August 2023.

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

The Judges

Enter Now

Ready to submit your entry to the Global Generics & Biosimilars Awards 2023? Enter today to be in with a chance of winning

Enter Now

Want to sponsor an award?

Sponsorship of the 10th Anniversary Global Generics & Biosimilars awards provides exclusive opportunities, targeted branding, thought leadership and lead generation. Seize the opportunity to come together, to educate and engage with the companies who matter to you most.

Sponsor Opportunities

Book your place

Looking to attend the 10th Anniversary Global Generics and Biosimilars Awards 2023? Book your place today!

Book your place

Headline Sponsor

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. IQVIA creates intelligent connections to deliver powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 86,000 employees, IQVIA conducts operations in more than 100 countries. Learn more at www.iqvia.com

our 2023 sponsors

Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 70 countries and for over 90 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering highest quality differentiated products and services to our partners. At Adalvo, we know that our partners like to be bigger, better and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customised to our partners, and is designed to challenge the status quo: together, this helps our partners achieve their business goals. We take pride in our ability to help its partners reach their goals – be those increasing revenues or pushing into new markets.

Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities. Adalvo tirelessly strives for excellence in all of its endeavours, driven by a deep-rooted passion to making a difference for partners and improve the lives of patients around the world.

Since its foundation in 2009, Pharmacloud has steadily built up its reputation as a provider of specialist advice and consultancy to both the pharma industry and financial investors. We offer a number of services, with a particular focus on commercial due diligence on off-patent products. However, we also work with big pharma companies on generic defence strategies, as well as with emerging pharma companies seeking to assess the potential market for their value-added generic products or biosimilars.

The research side of our business is currently being built up, starting from the base of our well-regarded industry blog. Look out for the first in our series of in-depth reports beginning in 2015.

Pharmawise is a leading boutique consulting firm focused on generic and biosimilar market expertise. Since 2006, we have conducted 150+ projects for leading financial institutions, generic and pharmaceutical companies, spanning:

  • due-diligence, acquisition screening and post-deal support
  • portfolio optimization and pipeline design or selection
  • mature brand strategy and life cycle management
  • product or portfolio in-licensing and out-licensing
  • quality, pharmacovigilance and regulatory audits
  • operational and supply chain optimization
  • product and process development
  • organizational design and culture
  • intellectual property and patents
  • strategy development

We match deep know-how and know-who to your generic or biosimilar needs: our project teams include highly knowledgeable experts with ~20 years executive experience and networks at successful global or local generic companies and leading management consulting firms in the above-mentioned areas.

If your responsibilities match our expertise, we would love to hear from you. Contact us at www.pharma-wise.com

our 2023 supporters

The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. Adopting a patient centric approach, IGBA works to improve patients’ access to quality-assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. For more details, regarding IGBA and its member associations, see the IGBA website at: www.igbamedicines.org

In communities around the world affected by chronic poverty, conflict or disasters, easily treatable diseases can mean chronic pain, poor quality of life or even a death sentence. International Health Partners (IHP) was founded in 2003 with a vision to radically enhance access to medicine to the world’s most vulnerable people. IHP enable targeted donations of medicines from a network of over 60 healthcare companies across Europe, and coordinate the safe and responsible supply of these to disaster hit and vulnerable communities across the world. IHP are the only organisation working to this model in the UK. In the last three years IHP have sent over 8.2 million treatments, with a value of over £34.5 million.

PREVIOUS Global Generics & Biosimilars Award CEREMONIES

Want to view previous Global Generics & Biosimilars Awards? Take a look back at our previous Awards and winners.

2022
GLOBAL GENERICS & BIOSIMILARS AWARDS 2022

November 2, 2022

2021
GLOBAL GENERICS & BIOSIMILARS AWARDS 2021

November 10, 2021

2020
GLOBAL GENERICS & BIOSIMILARS AWARDS 2020

November 3, 2020

got a question about the awards?

Please enter your name
Please enter your email
Please enter your valid email
Please enter your question
Please accept the terms & conditions
Senior Events Manager

jo.kirkpatrick@informa.com